Abstract: Improved receptor assays for the detection of thyroid stimulating hormone receptor (TSHR) autoantibodies are described which use immobilized, affinity-purified rTSHR preparations as specific binders. This format, as well as novel measures for neutralizing pathologically increased human TSH (hTSH) levels in the sera, e.g., by the addition of anti-hHSH antibody, and/or eliminating the influence of anti-bovine TSH antibody, result in increased assay reliability and open up the possibility of preparing the assay constituents in a ready to use and/or well-standardized form for automatic processing and/or convenient marketing.
Type:
Grant
Filed:
January 13, 1999
Date of Patent:
March 21, 2006
Assignee:
B.R.A.H.M.S Aktiengesellschaft
Inventors:
Andreas Bergmann, Joachim Struck, Nils Morgenthaler, Wolfgang Weglöhner, Jörg-Michael Hollidt
Abstract: Disclosed are uses of Gangliosides GM1 and/or asialo-GM1 substances simulating the carbohydrate portion of said gangliosides with regard to bonding to anti-GM1 antibodies and/or anti-ADM1 antibodies for producing agents which bind or block anti-GM1 antibodies and/or anti-AGM1 antibodies which bond to natural killer cells (NKC) or for blocking antigen-presenting cells and producing a T-cell anergy, and for producing an affinity material for the extracorporeal removal of anti-GM1 antibodies and/or anti-AGM1 antibodies in order to prevent, inhibit, and treat malignant cancers.
Abstract: Disclosed are uses of Gangliosides GM1 and/or asialo-GM1 substances simulating the carbohydrate portion of said gangliosides with regard to bonding to anti-GM1 antibodies and/or anti-ADM1 antibodies for producing agents which bind or block anti-GM1 antibodies and/or anti-AGM1 antibodies which bond to natural killer cells (NKC) or for blocking antigen-presenting cells and producing a T-cell anergy, and for producing an affinity material for the extracorporeal removal of anti-GM1 antibodies and/or anti-AGM1 antibodies I order to prevent, inhibit, and treat malignant cancers.
Abstract: Uses of glycine N-acyltransferase (GNAT) from body fluids or body tissues in human and veterinary medicine as a marker peptide for diagnosis, for prognosis and for monitoring the course of inflammations and infections and/or as a target for therapeutically influencing the course of inflammations and/or infections.
Type:
Application
Filed:
November 29, 2002
Publication date:
February 16, 2006
Applicant:
B.R.A.H.M.S Aktiengesellschaft
Inventors:
Andreas Bergmann, Joachim Struck, Monika Uhlein
Abstract: Uses of aldose 1-epimerase (SEQ ID NO:3) from body fluids or body tissues in human and veterinary medicine as a marker peptide for diagnosis, for prognosis of the course and for monitoring of the course of inflammations and infections and/or as a target for therapeutically influencing the course of inflammations and/or infections.
Type:
Application
Filed:
November 29, 2002
Publication date:
June 16, 2005
Applicant:
B.R.A.H.M.S. Aktiengesellschaft
Inventors:
Andreas Bergmann, Joachim Struck, Monika Uhlein
Abstract: Methods for diagnosis, early diagnosis, differential diagnosis, assessment of the severity and therapy-accompanying monitoring and prognosis of chronically inflammatory intestinal diseases (Crohn's disease, Colitis ulcerosa), in which the presence and/or the amount of one or more antibodies which bind to ribosomal proteins, in particular P0 and L5, are determined in the serum, plasma, tissue samples and/or stool of a patient who is suffering from a chronically inflammatory intestinal disease or in whom such a disease is suspected. The blocking or removal of such antibodies and/or the influencing of antigen-presenting cells or specifically reactive T-cells which react to ribosomal proteins, such as P0 and L5, by suitable agents can be therapeutically utilized.
Type:
Application
Filed:
September 3, 2002
Publication date:
April 7, 2005
Applicant:
B.R.A.H.M.S. Aktiengesellschaft
Inventors:
Andreas Bergmann, Marita Willnich, Detlef Schuppan
Abstract: Uses of recombinant procalcitonin 3-116 in the diagnosis and therapy of septic diseases and the measurement of prohormones other than procalcitonin, and of dipeptidyl peptidase IV, as biomarkers in the diagnosis of sepsis.
Type:
Application
Filed:
March 25, 2004
Publication date:
September 16, 2004
Applicant:
B.R.A.H.M.S Aktiengesellschaft
Inventors:
Andreas Bergmann, Joachim Struck, Wolfgang Weglohner
Abstract: Uses of recombinant procalcitonin 3-116 in the diagnosis and therapy of septic diseases and the measurement of prohormones other than procalcitonin, and of dipeptidyl peptidase IV, as biomarkers in the diagnosis of sepsis.
Type:
Grant
Filed:
May 29, 2001
Date of Patent:
June 29, 2004
Assignee:
B.R.A.H.M.S Aktiengesellschaft
Inventors:
Andreas Bergmann, Joachim Struck, Wolfgang Weglöhner
Abstract: In a competitive receptor binding assay for detecting TSH-receptor auto-antibodies in a biological sample, the sample is reacted in a reaction mixture which contains (i) a TSH-receptor or TSH-receptor preparation; (ii) a primary competitor, for example labelled TSH; and (iii) an agent for separating a complex composed of the TSH-receptor and the elements bound thereto of the reaction mixture from the liquid phase. According to the invention, the reaction is carried out in the presence of at least one monoclonal or polyclonal antibody specific against a partial peptide sequence of the TSH eceptor. This specific antibody is used to immobilize a complex of TSH-receptor and primary competitor and/or as secondary competitor for another part of the TSH-receptor auto-antibodies expected in a sample. The primary or secondary competitors are or can be selectively labelled.